Towards a vaccine against Ebola virus.
Towards a vaccine against Ebola virus.
复制标题
DOI：
10.1586/14760584.2.6.777
复制
发表时间：
2003-12-01
影响因子：
6.2
通讯作者：
Jahrling, Peter B
中科院分区：
文献类型：
--
作者：
Geisbert, Thomas W;Jahrling, Peter B
埃博拉病毒感染引起出血热，在人类和非人灵长类动物中具有高死亡率。目前，还没有批准用于人类的疫苗或疗法。埃博拉病毒的爆发并不频繁，主要局限于非洲的偏远地区，对病人的隔离在控制流行病方面是有效的。过去，这个小型的全球市场对开发埃博拉病毒疫苗几乎没有产生商业兴趣。然而，由于2001年9月11日前后发生的事件，人们对生物恐怖主义的认识有所提高，同时也知道前苏联正在评估埃博拉病毒作为一种武器，这极大地改变了人们对埃博拉病毒疫苗需求的看法。本综述简要回顾了开发有效疫苗的尝试，概述了目前的候选疫苗，并强调了具有最大商业开发潜力的策略。
Ebola virus infection causes hemorrhagic fever with high mortality rates in humans and nonhuman primates. Currently, there are no vaccines or therapies approved for human use. Outbreaks of Ebola virus have been infrequent, largely confined to remote locations in Africa and quarantine of sick patients has been effective in controlling epidemics. In the past, this small global market has generated little commercial interest for developing an Ebola virus vaccine. However, heightened awareness of bioterrorism advanced by the events surrounding September 11, 2001, concomitant with knowledge that the former Soviet Union was evaluating Ebola virus as a weapon, has dramatically changed perspectives regarding the need for a vaccine against Ebola virus. This review takes a brief historic look at attempts to develop an efficacious vaccine, provides an overview of current vaccine candidates and highlights strategies that have the greatest potential for commercial development.